Centre for Human Drug Research (CHDR), Leiden, The Netherlands.
Eur J Pain. 2018 Aug;22(7):1331-1342. doi: 10.1002/ejp.1222. Epub 2018 Apr 25.
A battery of evoked pain tasks (PainCart) was developed to investigate the pharmacodynamic properties of novel analgesics in early-phase clinical research. As part of its clinical validation, compounds with different pharmacological mechanisms of actions are investigated. The aim was to investigate the analgesic effects of classic and nonclassic analgesics compared to a sedating negative control in a randomized placebo-controlled crossover study in 24 healthy volunteers using the PainCart.
The PainCart consisted of pain tasks eliciting electrical, pressure, heat, cold and inflammatory pain. Subjective scales for cognitive functioning and psychotomimetic effects were included. Subjects were administered each of the following oral treatments: paracetamol (1000 mg), Δ9-THC (10 mg), promethazine (50 mg) or matching placebo. Pharmacodynamic measurements were performed at baseline and repeated up to 10 h postdose.
Paracetamol did not show a significant reduction in pain sensation or subjective cognitive functioning compared to placebo. Promethazine induced a statistically significant reduction in PTT for cold pressor and pressure stimulation. Furthermore, reduced subjective alertness was observed. Δ9-THC showed a statistically significant decrease in PTT for electrical and pressure stimulation. Δ9-THC also demonstrated subjective effects, including changes in alertness and calmness, as well as feeling high and psychotomimetic effects.
This study found a decreased pain tolerance due to Δ9-THC and promethazine, or lack thereof, using an evoked pain task battery. Pain thresholds following paracetamol administration remained unchanged, which may be due to insufficient statistical power. We showed that pain thresholds determined using this pain test battery are not driven by sedation.
The multimodal battery of evoked pain tasks utilized in this study may play an important role in early-phase clinical drug development. This battery of pain tasks is not sensitive to the effects of sedation alone, and thus suitable to investigate the analgesic potential of novel analgesic compounds.
一套诱发疼痛任务(PainCart)被开发出来,用于在早期临床研究中研究新型镇痛药的药效学特性。作为其临床验证的一部分,研究了具有不同作用机制的化合物。目的是在 24 名健康志愿者中,使用 PainCart 进行一项随机安慰剂对照交叉研究,比较经典和非经典镇痛药与镇静性负性对照药物的镇痛效果。
PainCart 由诱发电、压、热、冷和炎性疼痛的疼痛任务组成。包括用于认知功能和精神拟态效应的主观量表。受试者接受以下口服治疗中的每一种:对乙酰氨基酚(1000mg)、Δ9-四氢大麻酚(10mg)、异丙嗪(50mg)或匹配的安慰剂。在基线和重复至给药后 10 小时进行药效学测量。
与安慰剂相比,对乙酰氨基酚在疼痛感觉或主观认知功能方面没有显著降低。异丙嗪诱导冷压和压力刺激的 PTT 显著降低。此外,观察到主观警觉性降低。Δ9-四氢大麻酚在电和压力刺激的 PTT 上显示出统计学上的显著降低。Δ9-四氢大麻酚也表现出主观效应,包括警觉性和镇静感的变化,以及感觉兴奋和精神拟态效应。
本研究发现,使用诱发疼痛任务电池,Δ9-四氢大麻酚和异丙嗪可降低疼痛耐受力,而对乙酰氨基酚则没有。对乙酰氨基酚给药后疼痛阈值保持不变,这可能是由于统计效力不足。我们表明,使用这种疼痛测试电池确定的疼痛阈值不受镇静作用的驱动。
本研究中使用的多模式诱发疼痛任务电池可能在早期临床药物开发中发挥重要作用。该疼痛任务电池对单独的镇静作用不敏感,因此适合研究新型镇痛化合物的镇痛潜力。